Immunoglobulin alpha Fc receptor (CD89)

The Immunoglobulin alpha Fc receptor (CD89) is a transmembrane glycoprotein expressed primarily on the surface of myeloid lineage cells, including neutrophils, monocytes, macrophages, and eosinophils [1][2]. It serves as the specific receptor for the Fc portion of Immunoglobulin A (IgA), the most abundant antibody class at mucosal surfaces [3]. Upon binding to polymeric IgA or IgA-coated pathogens, CD89 associates with the Fc receptor gamma-chain (FcRγ) to initiate intracellular signaling through immunoreceptor tyrosine-based activation motifs (ITAMs) [1][5]. This process triggers potent effector functions such as phagocytosis, respiratory burst, and antibody-dependent cellular cytotoxicity (ADCC), making it a critical component of the host's defense against infections [3][6]. In the context of disease, CD89 is heavily implicated in the pathogenesis of IgA nephropathy, where the shedding of soluble CD89 and the formation of IgA-CD89 complexes contribute to renal inflammation and glomerular damage [4][7]. Therapeutically, CD89 is being explored as a target for bispecific antibodies designed to recruit and activate neutrophils against tumor cells, offering a unique pathway for cancer immunotherapy that bypasses traditional NK cell-mediated mechanisms [6][8]. Additionally, modulating CD89 signaling is a point of interest for treating chronic inflammatory and autoimmune conditions where IgA-mediated activation is dysregulated [5][7]. Sources: [1] UniProt (P24071); [2] NCBI Gene (2204); [3] Morton & Bakker, 'CD89: a multi-faceted receptor', 2001; [4] Monteiro et al., 'Pathogenesis of IgA nephropathy', 2003; [5] Pasquier et al., 'CD89-mediated inflammation', 2005; [6] Brandsma et al., 'Therapeutic antibodies targeting CD89', 2015; [7] Aleyd et al., 'IgA complexes in health and disease', 2015; [8] Boross et al., 'The role of CD89 in antibody therapy', 2013.

Other names

Fc alpha receptorFCARCD89 antigenFcaR

Binding of IgA or therapeutic antibodies to CD89 triggers the recruitment of the Fc receptor gamma-chain (FcRγ), leading to ITAM-mediated signaling that activates myeloid effector functions such as phagocytosis and ADCC. Conversely, monomeric IgA binding in the absence of cross-linking can mediate inhibitory signals through 'inhibitory ITAM' (ITAMi) configurations.